Ultralife (NASDAQ:ULBI - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "strong-buy" rating to a "hold" rating in a note issued to investors on Saturday.
Ultralife Price Performance
NASDAQ:ULBI opened at $6.85 on Friday. The stock has a market cap of $113.98 million, a P/E ratio of 36.05 and a beta of 1.08. Ultralife has a one year low of $4.07 and a one year high of $10.09. The company has a fifty day moving average price of $7.64 and a 200 day moving average price of $6.55. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.31 and a quick ratio of 1.62.
Ultralife (NASDAQ:ULBI - Get Free Report) last released its earnings results on Thursday, August 7th. The technology company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.07). Ultralife had a net margin of 1.79% and a return on equity of 2.68%. The company had revenue of $48.56 million for the quarter, compared to analyst estimates of $51.00 million.
Insider Activity at Ultralife
In other news, Director Bradford T. Whitmore acquired 29,766 shares of Ultralife stock in a transaction on Thursday, August 21st. The stock was bought at an average price of $6.63 per share, for a total transaction of $197,348.58. Following the transaction, the director owned 1,128,731 shares of the company's stock, valued at $7,483,486.53. The trade was a 2.71% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders purchased 58,664 shares of company stock valued at $387,049. 40.00% of the stock is currently owned by company insiders.
Institutional Trading of Ultralife
A number of hedge funds have recently modified their holdings of the company. IFP Advisors Inc lifted its position in shares of Ultralife by 24.6% in the 1st quarter. IFP Advisors Inc now owns 14,200 shares of the technology company's stock worth $76,000 after acquiring an additional 2,800 shares during the period. Bank of America Corp DE lifted its position in shares of Ultralife by 30.7% in the 4th quarter. Bank of America Corp DE now owns 12,067 shares of the technology company's stock worth $90,000 after acquiring an additional 2,836 shares during the period. Pitti Group Wealth Management LLC lifted its position in shares of Ultralife by 23.4% in the 1st quarter. Pitti Group Wealth Management LLC now owns 21,120 shares of the technology company's stock worth $114,000 after acquiring an additional 4,000 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Ultralife by 1.1% in the 2nd quarter. Janney Montgomery Scott LLC now owns 446,250 shares of the technology company's stock worth $4,007,000 after acquiring an additional 5,000 shares during the period. Finally, Lazard Asset Management LLC lifted its position in shares of Ultralife by 1,650.0% in the 2nd quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company's stock worth $49,000 after acquiring an additional 5,247 shares during the period. Institutional investors own 30.68% of the company's stock.
About Ultralife
(
Get Free Report)
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.